drugset / Trial / NCT02782624

Relative Bioavailability of BI 10773 Administered Twice Daily Compared BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female Volunteers

NCT02782624

Phase 1 Completed 16 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-label

Summary

To investigate the influence of different dosage regimen (5 mg twice daily versus 10 mg once daily) on the steady state pharmacokinetics and pharmacodynamics of BI 10773 administered orally

Timeline

Start
2009-09
Primary completion
2009-11
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 5 mg Oral
Subject Empagliflozin Small molecule 10 mg Oral
Subject Empagliflozin Small molecule

Indications

No indication recorded.